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Abstract
Background: Candida glabrata has emerged as an important human pathogen associated with systemic and mucosal
infections. Here, we describe isolation of two cholesterol-dependent Candida glabrata strains from a candidemia
patient which failed to grow on the media devoid of a cholesterol source.
Methods: Both the isolates were recovered from BACTEC Plus Aerobic/F blood culture bottles of a candidemic
patient. Since these isolates failed to grow on Sabouraud dextrose agar, Mueller-Hinton agar and RPMI 1640 agar
media, their definitive identification required PCR sequencing of the internally transcribed spacer (ITS)1 and ITS2
regions of rDNA and the D1/D2 region sequences within 26S rRNA gene. The cholesterol auxotrophy was determined
by their ability to grow on media containing a cholesterol source. The minimum inhibitory concentrations (MICs) to
antifungal agents were determined by Etest.
Results: The identity of the isolates was confirmed by sequencing of the ITS1 and ITS2 regions of rDNA and the
D1/D2 region sequences within 26S rRNA gene and also by matrix-assisted laser desorption and ionization–time-
of-flight mass spectrometry with 99.9% confidence value. Both the isolates showed good growth only when media
were supplemented with cholesterol, oxbile or blood. Additionally, these isolates were resistant to amphotericin B
(MIC ≥32 μg/ml), fluconazole (MIC ≥256 μg/ml), voriconazole (MIC ≥32 μg/ml), itraconazole (MIC ≥32 μg/ml), and
posaconazole (MIC ≥32 μg/ml), but susceptible to caspofungin (MIC range 0.064 to 0.19 μg/ml).
Conclusion: This appears to be the first report on isolation of cholesterol-dependent strains of C. glabrata from a
candidemia patient exhibiting resistance to azoles and amphotericin B. Further, the report demonstrates that
induction of cholesterol/sterol auxotrophy is associated with resistance to antifungal drugs targeting ergosterol
biosynthesis. These observations may have therapeutic implications for the treatment of infections caused by such
C. glabrata strains.
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Background
Candida glabrata has emerged as the second most im-
portant yeast associated with mucosal and systemic infec-
tions in critically ill patients in some tertiary care hospitals
in North America [1]. The species is intrinsically less sus-
ceptible to azoles and it is generally believed that extensive
topical and systemic use of these drugs might have con-
tributed to its rising incidence as a human pathogen.
There are multiple mechanisms that impart resistance
against azoles. These include alterations in ERG11 gene
that encodes for 14- α-methyl sterol demethylase in ergos-
terol biosynthesis and/or upregulation of efflux pumps
encoded by CgCDR1 and CgCDR2 genes [2-4]. Addition-
ally, alterations in ERG3 gene encoding Δ5,6 sterol desatur-
ase have been noted in strains carrying mutations in ERG11
to allow survival under aerobic conditions [5]. Here, we de-
scribe the isolation of two C. glabrata strains from blood-
stream of a candidemia patient which required exogenous
cholesterol/sterol for growth in media that are routinely
used in clinical mycology laboratories.
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Methods
Isolation of C. glabrata strains
The isolates, Kw1018/12 and Kw1154/12, were obtained
9 days apart from two blood samples at Al-Amiri hospital,
Kuwait. Initially, the isolates grew slowly in BACTEC
Plus blood culture bottles with detection time of 54 and
75 hours, respectively and were tentatively identified by
Vitek2 yeast identification system as C. glabrata. The
isolates were received at Mycology Reference Laboratory,
Faculty of Medicine, Kuwait University for further identifi-
cation and antifungal susceptibility testing. When the iso-
lates were subcultured on Sabouraud dextrose agar (SDA),
they failed to grow. Similarly, no growth was obtained on
RPMI medium with 2% glucose and Mueller-Hinton agar
(MHA). Surprisingly, the isolates grew well on blood agar
and chocolate agar. Addition of oxbile (2%), cholesterol
(20 μg/ml) or sheep blood (5%) to SDA, MHA or RPMI
supported good growth of the isolates.
Molecular characterization of the isolates
Further species-specific identification of the cultured iso-
lates was carried out by PCR sequencing of the internally
transcribed spacer (ITS)1 and ITS2 regions of rDNA
and the D1/D2 region sequences within 26S rRNA gene.
Genomic DNA from the isolates was prepared and the ITS
region of rDNA and D1/D2 regions of 26S rRNA gene were
amplified and sequenced as described previously [6,7].
PCR Sequencing of ERG11 and ERG3 genes
The complete ERG11 gene (including 5′ and 3′ untrans-
lated regions) was amplified by PCR using rTth DNA
polymerase (Applied Biosystems, Foster City, CA, USA),
ERG11F (5′-TCCACCTCGAACCCGTATA-3′) and ERG11R
(5′-TCCATGTTGATATTCACGATGACT-3′) primers and
by following the amplification and cycling conditions
described previously [8]. The 1923 bp amplicons were
sequenced by using Big-Dye terminator cycle sequencing
kits (Applied Biosystems) and automated DNA sequencer







TCAATAGGTT-3′), or ERG11RS4 (5′-AGTAAGCAGCT
TCAGCGGAAACA-3′) as sequencing primer [8]. The
complete ERG3 gene (including 5′ and 3′ untranslated
regions) was also amplified by PCR using rTth DNA
polymerase, ERG3F (5′-AGAGATGAGGCCTGGAAG
AAGA-3′) and ERG3R (5′-AAATATGAGAACCCAGG
TCAGCA-3′) primers and by following the amplification
and cycling conditions described previously [8]. The









cing primer [8]. The complete ERG11 and ERG3 gene
sequences were assembled and were compared with the
corresponding sequences from reference C. glabrata
strain 2001-L5 by using the program Clustal Omega
(http://www.ebi.ac.uk/Tools/msa/clustalo/) [5].
Antifungal susceptibility
Since both bloodstream C. glabrata strains failed to grow
on RPMI medium, minimum inhibitory concentrations
(MICs) were determined by Etest on RPMI medium con-
taining 2% glucose and supplemented with cholesterol
(20 μg/ml) and Mueller-Hinton agar (MHA) medium sup-
plemented with cholesterol (20 μg/ml) or 5% sheep blood.
For comparison, C. glabrata strain (ATCC 90030) and a
recent blood culture isolate (Kw2273/13) were used as
controls. The Etest method was performed using Etest
strips (bioMérieux, Marcy-ĺEtoile, France) for fluconazole,
itraconazole, voriconazole, caspofungin and amphotericin
B. A standardized inoculum suspension of each isolate
equivalent to a 0.5 McFarland standard was prepared.
Plates were inoculated uniformly with cotton swab and
allowed to dry before Etest strips were applied. MICs were
determined after 48 h of incubation at 35°C. Azole MICs
were read as the lowest concentrations producing an
80% reduction of growth. The isolates were considered
resistant following the breakpoints described recently
for Candida spp. [9].
Since these investigations were part of the routine diag-
nostic service offered by Mycology Reference Laboratory,
no patient consent was required.
Results
Growth requirement
The isolates showed moderate to good growth on blood
agar, chocolate agar and routine culture media supple-
mented with oxbile (2%), cholesterol (20 μg/ml) or sheep
blood (5%).
Molecular characterization
The complete ITS and D1/D2 region sequences of isolates
Kw1018/12 and Kw1154/12 were assembled and the cor-
responding sequences from the two isolates were identical.
In BLAST searches (http://www.ncbi.nlm.nih.gov/BLAST/
Blast.cgi?), the ITS and D1/D2 region sequences of isolates
Kw1018/12 and Kw1154/12 (EMBL accession nos. HE
993756/7 and HE 998775/6, respectively) showed only 7
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and 1 nucleotide differences with the corresponding se-
quences from reference C. glabrata strain (CBS 138). The
ITS region sequence is also available from another refer-
ence C. glabrata strain (ATCC 90030) and showed only 1
nucleotide difference with the corresponding sequences
from isolates Kw1018/12 and Kw1154/12. Thus, the ITS
and/or D1/D2 region sequences of both the isolates exhib-
ited >99% sequence identity with the corresponding se-
quences from the reference C. glabrata strains confirming
their identity as C. glabrata. The species-specific identity
of the isolates was also confirmed by matrix-assisted laser
desorption and ionization–time-of-flight mass spectrom-
etry (MALDI–TOF MS; bioMeriuex) with 99.9% confi-
dence value.
The ERG11 gene sequences of our isolates (EMBL acces-
sion number HF952117) showed four synonymous muta-
tions within the coding region compared to the sequence
from reference C. glabrata strain 2001-L5 [5]. Similarly, the
ERG3 gene sequences of our isolates (EMBL accession
number HF952118) showed three synonymous mutations
within the coding region compared to the sequence from
reference C. glabrata strain 2001-L5. No non-synonymous
mutations were detected and no promoter mutations were
apparent in both ERG11 and ERG3 genes.
Antifungal susceptibility
Both our auxotrophic C. glabrata strains were resist-
ant to amphotericin B (MIC ≥32 μg/ml), fluconazole
(MIC ≥256 μg/ml), voriconazole (MIC ≥32 μg/ml), itracona-
zole (MIC ≥32 μg/ml), and posaconazole (MIC ≥32 μg/ml),
but appeared susceptible to caspofungin (MIC range 0.064
to 0.19 μg/ml) on all the media used (Figure 1, Table 1)
[9]. In contrast, the MICs of control strain of C. glabrata
(ATCC 90030) as well as of a recent blood culture isolate
(Kw2273/13) were within susceptible range (Table 1).
Discussion
A literature review revealed that some strains of C. glabrata
require exogenous supply of cholesterol for their growth
[10-12]. Both our blood culture isolates grew on blood
agar and chocolate agar, but exhibited growth on SDA,
RPMI agar or MHA only when supplemented with
oxbile (2%), cholesterol (20 μg/ml) or sheep blood (5%).
Isolation of cholesterol-requiring C. glabrata strains
from candidemia patients may not be difficult since pa-
tient’s blood can serve as a source of cholesterol. How-
ever, C. glabrata strains requiring exogenous cholesterol
for growth have also been recovered from non-blood
specimens and were found to be resistant to antifungal
drugs that act on ergosterol biosynthesis [11,12]. Thus,
patients infected with such strains may pose significant
diagnostic and therapeutic challenges because of lack of
growth on routine culture media, but will exhibit in vivo
growth due to their ability to maintain integrity of cell
membrane by utilizing exogenous cholesterol available
in blood/tissue milieu. Consequently, such strains can
persist at the site of infection in spite of adequate therapy
with azoles or amphotericin B. Although cholesterol-
dependent strains of C. glabrata are rarely encountered, it
is possible that isolation of some such strains might be
missed if specimens are cultured only on routine media
(devoid of a cholesterol source). Here, it is pertinent to
mention that C. glabrata is prone to developing reduced
susceptibility/cross-resistance to multiple antifungal
agents without cholesterol/sterol auxotrophy [13-15].
Figure 1 Candida glabrata strain (Kw1018/12) showing Etest
MICs for caspofungin (CS, 0.094 μg/ml) (A) and amphotericin B
(AP, >32 μg/ml) (B) on Mueller-Hinton agar supplemented with
5% sheep blood and read after 48 h of incubation at 35°C.
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Table 1 Comparative antifungal susceptibility of C. glabrata strains on different media with and without cholesterol auxotrophy
Strain No Minimum inhibitory concentration (μg/ml) on
RPMI with 2% glucose RPMI with cholesterol (20 μg/ml) MHA with cholesterol (20 μg/ml) MHA with 5% sheep blood
AP FL VO IT PO CS AP FL VO IT POS CS AP FL VO IT POS CS AP FL VO IT POS CS
Kw1018/12 - - - - - - ≥32 ≥256 ≥32 ≥32 ≥32 0.125 ≥32 ≥256 ≥32 ≥32 ≥32 0.19 ≥32 ≥256 ≥32 ≥32 ≥32 0.094
Kw1154/12 - - - - - - ≥32 ≥256 ≥32 ≥32 ≥32 0.125 ≥32 ≥256 ≥32 ≥32 ≥32 0.19 ≥32 ≥256 ≥32 ≥32 ≥32 0.064
Kw2273/13 0.38 8 0.25 6 2 0.094 1 4 0.125 4 2 0.125 1 3 0.19 6 0.75 0.25 0.38 3 0.19 1 0.5 0.094



















The development of cholesterol auxotrophy seemingly
does not affect susceptibility to caspofungin or other
echinocandins, which is the treatment of choice for C.
glabrata infections [16].
The patient from whom the two isolates (Kw1018/12
and Kw1154/12) were recovered was initially treated
with liposomal amphotericin B (AmBisome, 5 mg/kg)
for three weeks and later with caspofungin (70 mg loading
dose, followed with 50 mg daily dose) for 7 days. However,
the patient died of multi-organ failure and septic shock. It
is probable that the appropriate therapy with caspofungin
was delayed in our patient until C. glabrata was isolated
and its resistance against amphotericin B and azoles was
determined.
The major mechanisms known to mediate resistance to
azoles in C. glabrata involve upregulation and/or other
mutations in ERG11 and efflux pumps. However, resist-
ance to azoles in our isolates was not due to mutations in
ERG11 gene and non-synonymous mutations were also
not detected in the ERG3 gene. Although the nucleotide
sequences of both genes varied slightly, no promoter mu-
tations were detected and the encoded protein sequences
(EMBL accession numbers HF952117 and HF952118)
were also identical to reference C. glabrata strain 2001-L5
[5]. Upregulation of efflux pumps was not studied in the
present investigation. Thus, the molecular basis of resist-
ance to azoles in our isolates remained unidentified. It is
probable that upregulation of efflux pumps or mutation(s)
in some other genes that have been recently shown to
confer resistance to antifungal drugs in C. glabrata
are involved in our isolates [3,17-19]. Occurrence of
such strains poses a major threat for proper manage-
ment of such patients, particularly when resistance to
echinocandins among C. glabrata strains is also emer-
ging rapidly [20].
Conclusion
Two cholesterol-dependent C. glabrata strains isolated
from the blood of a candidemic patient are described.
The report demonstrates that induction of cholesterol/
sterol auxotrophy in C. glabrata may impart resistance
to antifungal drugs targeting ergosterol biosynthesis.
The observations may have therapeutic implications.
Early therapy with echinocandins may be optimal to
overcome the problem of triazole/amphotericin B resist-
ance in such isolates. A limitation of our study is that
the molecular basis of resistance to azoles in our isolates
remained unidentified as only two genes involved in er-
gosterol biosynthesis were studied while efflux pumps
that can also contribute towards resistance to azoles
were not investigated. To our knowledge, this is the first
report on the isolation of cholesterol-dependent strains
of C. glabrata from a candidemia patient exhibiting re-
sistance to azoles and amphotericin B.
Abbreviation
AP: Amphotericin B; FL: Fluconazole; VO: Voriconazole; IT: Itraconazole;
POS: Posaconazole; CS: Caspofungin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZUK and SA drafted the manuscript. LJ performed antifungal susceptibility
and molecular identification studies. KA collected the clinical data. All
authors read and approved the final version of the manuscript.
Acknowledgements
The authors are thankful to Ms. Sandhya Vayalil and Rachel Chandy for
technical support.
Author details
1Department of Microbiology, Faculty of Medicine, Kuwait University, P. O.
Box 24923, Safat 13110, Kuwait. 2Microbiology Unit, Al-Amiri Hospital, Safat,
Kuwait.
Received: 27 October 2013 Accepted: 31 March 2014
Published: 8 April 2014
References
1. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M: The changing
epidemiology of healthcare-associated candidemia over three decades.
Diagn Microbiol Infect Dis 2012, 73:45–48.
2. Pfaller MA: Antifungal drug resistance: mechanisms, epidemiology, and
consequences for treatment. Am J Med 2012, 125(Suppl):S3–13.
3. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G: Mechanisms
of azole resistance in clinical isolates of Candida glabrata collected
during a hospital survey of antifungal resistance. Antimicrob Agents
Chemother 2005, 49:668–679.
4. Hull CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Kelly DE,
Kelly SL: Facultative sterol uptake in an ergosterol-deficient clinical isolate
of Candida glabrata harboring a missense mutation in ERG11 and
exhibiting cross-resistance to azoles and amphotericin B. Antimicrob
Agents Chemother 2012, 56:4223–4232.
5. Geber A, Hitchcock CA, Swartz JE, Pullen FS, Marsden KE, Kwon-Chung KJ,
Bennett JE: Deletion of the Candida glabrata ERG3 and ERG11 genes:
effect on cell viability, cell growth, sterol composition, and antifungal
susceptibility. Antimicrob Agents Chemother 1995, 39:2708–2717.
6. Khan ZU, Ahmad S, Hagen F, Fell JW, Kowshik T, Chandy R, Boekhout T:
Cryptococcus randhawai sp. nov., a novel anamorphic basidiomycetous
yeast isolated from tree trunk hollow of Ficus religiosa (peepal tree) from
New Delhi, India. Antonie Van Leeuwenhoek 2010, 97:253–259.
7. Mokaddas E, Khan ZU, Ahmad S: Prevalence of Candida dubliniensis
among cancer patients in Kuwait: a 5-year retrospective study. Mycoses
2011, 54:e29–34.
8. Asadzadeh M, Ahmad S, Al-Sweih N, Khan ZU: Rapid molecular differentiation
and genotypic heterogeneity among Candida parapsilosis and Candida
orthopsilosis strains isolated from clinical specimens in Kuwait. J Med
Microbiol 2009, 58(Pt 6):745–752.
9. Pfaller MA, Diekema DJ: Progress in antifungal susceptibility testing of
Candida spp. by use of Clinical and Laboratory Standards Institute broth
microdilution methods, 2010 to 2012. J Clin Microbiol 2012, 50:2846–2856.
10. Bard M, Sturm AM, Pierson CA, Brown S, Rogers KM, Nabinger S, Eckstein J,
Barbuch R, Lees ND, Howell SA, Hazen KC: Sterol uptake in Candida
glabrata: rescue of sterol auxotrophic strains. Diagn Microbiol Infect Dis
2005, 52:285–293.
11. Hazen KC, Stei J, Darracott C, Breathnach A, May J, Howell SA: Isolation of
cholesterol-dependent Candida glabrata from clinical specimens. Diagn
Microbiol Infect Dis 2005, 52:35–37.
12. Rezusta A, Aspiroz C, Boekhout T, Cano JF, Theelen B, Guarro J, Rubio MC:
Cholesterol-dependent and amphotericin B resistant isolates of a
Candida glabrata strain from an Intensive Care Unit patient. Med Mycol
2008, 46:265–268.
13. Khan ZU, Ahmad S, Al-Obaid I, Al-Sweih NA, Joseph L, Farhat D: Emergence
of resistance to amphotericin B and triazoles in Candida glabrata vaginal
isolates in a case of recurrent vaginitis. J Chemother 2008, 20:488–491.
Khan et al. BMC Infectious Diseases 2014, 14:188 Page 5 of 6
http://www.biomedcentral.com/1471-2334/14/188
14. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD: Amphotericin B and
caspofungin resistance in Candida glabrata isolates recovered from a
critically ill patient. Clin Infect Dis 2006, 42:938–944.
15. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN:
Frequency of decreased susceptibility and resistance to echinocandins
among fluconazole-resistant bloodstream isolates of Candida glabrata.
J Clin Microbiol 2012, 50:1199–1203.
16. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE
Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH,
Walsh TJ, Sobel JD: Infectious Diseases Society of America. Clinical practice
guidelines for the management of candidiasis: 2009 update by the
Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503–535.
17. Vermitsky JP, Earhart KD, Smith WL, Homayouni R, Edlind TD, Rogers PD:
Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption
and genome-wide expression studies. Mol Microbiol 2006, 61:704–722.
18. Tsai HF, Sammons LR, Zhang X, Suffis SD, Su Q, Myers TG, Marr KA, Bennett JE:
Microarray and molecular analyses of the azole resistance mechanism in
Candida glabrata oropharyngeal isolates. Antimicrob Agents Chemother 2010,
54:3308–3317.
19. Farahyar S1, Zaini F, Kordbacheh P, Rezaie S, Safara M, Raoofian R, Heidari M:
Overexpression of aldo-keto-reductase in azole-resistant clinical isolates
of Candida glabrata determined by cDNA-AFLP. Daru 2013, 21:1.
20. Lewis JS 2nd, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH: Rapid
emergence of echinocandin resistance in Candida glabrata resulting in
clinical and microbiologic failure. Antimicrob Agents Chemother 2013,
57:4559–4561.
doi:10.1186/1471-2334-14-188
Cite this article as: Khan et al.: Isolation of cholesterol-dependent,
multidrug-resistant Candida glabrata strains from blood cultures of a
candidemia patient in Kuwait. BMC Infectious Diseases 2014 14:188.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Khan et al. BMC Infectious Diseases 2014, 14:188 Page 6 of 6
http://www.biomedcentral.com/1471-2334/14/188
